Proposal for Recombinant human Gas6 (catalog 886-G6, R&D Systems)

Overview of Therapeutic Candidate:
Recombinant human Gas6 (catalog 886-G6, R&D Systems) is a biologic version of the endogenous growth arrest–specific 6 protein (Gas6), a naturally occurring vitamin K–dependent protein discovered originally as a gene product expressed during growth arrest. This compound is synthesized using recombinant protein production platforms that ensure proper post-translational modification, including γ-carboxylation of its N-terminal Gla domain, which is essential for its biological activity; these modifications are critical to permitting its binding to phosphatidylserine (PS) on target cell membranes and for its high-affinity interaction with TAM (Tyro3, Axl, MerTK) receptor tyrosine kinases (Evans, 2016, pp. 14–18; Law et al., 2018, pp. 3–4). As a protein ligand, recombinant human Gas6 belongs to the class of biologics that are designed to mimic or augment endogenous signaling molecules, and its production employs established mammalian cell expression systems (e.g., HEK293) that can yield properly folded, fully γ-carboxylated protein with activity replicating that of the native ligand (Miao et al., 2024, pp. 21–22). This class of therapeutic compounds has been widely used in preclinical research to elucidate receptor–ligand interactions and downstream signaling pathways, as well as to modulate cellular functions such as efferocytosis, immune regulation, and inflammation; hence, the development platforms for such ligand proteins are well defined and are frequently repurposed for novel applications in areas such as oncology, inflammation, and even degenerative diseases (Bellan et al., 2016, pp. 3–4; Burstyn-Cohen, 2017, pp. 7–8).

Therapeutic History:
In preclinical studies, Gas6 has served as an essential tool to study TAM receptor activation, where its binding to receptors, particularly MerTK on the surface of retinal pigment epithelium (RPE) cells, has been shown to promote phagocytosis and cell survival (Albert et al., 2015, pp. 1–2; Inana et al., 2018, pp. 1–2). Although Gas6 has not been trialed in registered clinical studies specifically for dry age-related macular degeneration (AMD) (ClinicalTrials.gov, n.d.), it has been extensively evaluated in various in vitro and animal models to understand its role in modulating efferocytosis and inflammatory responses in tissues ranging from immune cells to neural and retinal cells (ClinicalTrials.gov, n.d.; Evans, 2016, pp. 9–14). In experimental models of retinal dysfunction, particularly in RPE cell cultures and preclinical animal models such as the Royal College of Surgeons (RCS) rat, impairment of MerTK signaling has been directly linked to defective clearance of photoreceptor outer segments and consequent retinal degeneration (Inana et al., 2018, pp. 11–12; Müller & Finnemann, 2020, pp. 270–272). Recombinant Gas6 has been used primarily to explore the mechanistic aspects of MerTK activation, whereby its administration restored phagocytic capability in RPE cells with intact MerTK signaling, suggesting that this ligand can rescue phagocytic deficits under experimental conditions (Albert et al., 2015, pp. 10–11; Tasnim, 2020, pp. 20–23). Although its clinical application in dry AMD has yet to be established, the therapeutic principle is built on a strong preclinical foundation that supports further translational investigation (Miao et al., 2024, pp. 21–22; Parinot, 2015, pp. 109–112).

Mechanism of Action:
Biochemically, Gas6 is known for its high degree of specificity as a ligand for the TAM receptor family by virtue of its bifunctional domains: the N-terminal Gla domain, which requires vitamin K–dependent γ-carboxylation, binds to phosphatidylserine expressed on the surface of apoptotic cells or cellular debris; and the C-terminal laminin G and SHBG domains, which mediate interaction with TAM receptors including Axl, Tyro3, and particularly MerTK, albeit with varying affinities (Law et al., 2018, pp. 3–4; Tasnim, 2020, pp. 20–23). Upon binding, Gas6 triggers receptor dimerization and autophosphorylation of the intracellular tyrosine kinase domain of MerTK; this activation leads to the recruitment and activation of downstream effectors such as PI3K/Akt, Rho GTPases, and cytoskeletal regulators that collectively promote actin-driven engulfment and phagosome formation (Parinot, 2015, pp. 109–112; Yefimova et al., 2021, pp. 17–19). In RPE cells, the activation of MerTK by Gas6 is central to the phagocytic clearance of photoreceptor outer segments, a daily renewal process essential to maintain retinal homeostasis and prevent the accumulation of toxic debris, which would otherwise lead to inflammation, oxidative stress, and subsequent cell death (Inana et al., 2018, p. 15; Law et al., 2015, pp. 7–8). The molecular interactions involve not only direct ligand–receptor binding but also modulation by other accessory molecules such as integrins (for instance, αvβ5 integrin), which work in concert with MerTK to ensure efficient phagocytosis (Albert et al., 2015, p. 12). Additionally, there is evidence that Gas6 engagement may lead to the internalization of the receptor and its subsequent recycling, which is crucial for sustained phagocytic activity within the RPE (Evans, 2016, pp. 9–14). This precise mechanism of action is supported by extensive biochemical studies that delineate the structure–function relationship of Gas6 and its role in MerTK-mediated signaling cascades (Davra et al., 2016, pp. 12–14; Huelse et al., 2020, pp. 4–6).

Expected Effect:
The central hypothesis for using recombinant Gas6 in dry AMD is predicated on its ability to enhance MerTK receptor activation on RPE cells, thereby restoring or augmenting their phagocytic capacity. In the context of dry AMD, where dysfunctional RPE phagocytosis leads to the accumulation of photoreceptor outer segment debris, impaired clearance results in subretinal deposit formation, chronic inflammation, and ultimately retinal degeneration (Inana et al., 2018, pp. 11–12; Parinot, 2015, pp. 109–112). By supplementing recombinant Gas6, the expected outcome is the reactivation of the MerTK signaling pathways that drive actin-mediated engulfment processes, leading to improved clearance of photoreceptor debris and restoration of the physiological balance in the retinal microenvironment (Miao et al., 2024, pp. 20–21; Tasnim, 2020, pp. 20–23). Since MerTK is robustly expressed in RPE cells and is a known mediator of photoreceptor outer segment clearance, activating this receptor with Gas6 should lead to enhanced downstream signaling via the PI3K/Akt pathway, promoting anti-apoptotic effects and preventing RPE cell death (Evans, 2016, pp. 14–18; Unknown Reference). In experimental assays, one would expect to observe increased phagocytic activity, as evidenced by enhanced internalization of labeled photoreceptor outer segments by RPE cultures, reduction in accumulation of debris, and improvement in markers of cell survival and reduced inflammation (Yefimova et al., 2021, pp. 17–19; Parinot et al., 2024, pp. 2–4). Furthermore, because Gas6 is a natural ligand with a well-defined receptor specificity profile, its application is anticipated to produce selective activation of MerTK with minimal off-target activity on other receptor families, thereby reducing the risk of unintended consequences (Bellan et al., 2016, pp. 3–4; Burstyn-Cohen, 2017, pp. 7–8).

Overall Evaluation:
Recombinant human Gas6 stands out as a promising translational candidate for dry AMD therapy based on several key strengths. The foremost strength is its biological relevance; Gas6 is an endogenous ligand that naturally engages MerTK, a receptor whose function is critical for RPE phagocytosis and retinal homeostasis. This mechanistic clarity is supported by a breadth of biochemical evidence demonstrating that Gas6 binding leads to receptor dimerization, autophosphorylation, and activation of downstream signaling cascades that orchestrate cytoskeletal remodeling and phagosome formation (Parinot, 2015, pp. 109–112; Tasnim, 2020, pp. 20–23). Furthermore, preclinical studies have shown that deficiencies in MerTK signaling lead to retinal degenerative phenotypes, and that restoration of this pathway can rescue phagocytic function (Inana et al., 2018, p. 15; Müller & Finnemann, 2020, pp. 270–272). This provides a strong rationale for employing recombinant Gas6 to correct the underlying phagocytic dysfunction observed in dry AMD.

Another significant advantage lies in the well-established production platforms for recombinant proteins. The production of recombinant human Gas6, as evidenced by catalog 886-G6 from R&D Systems, is based on robust manufacturing protocols that ensure homogeneity, proper folding, and requisite post-translational modifications, such as vitamin K–dependent γ-carboxylation, which are essential for its full biological activity (Miao et al., 2024, pp. 20–21; Law et al., 2018, pp. 3–4). This reduces the risk typically associated with novel chemical entities and enables quicker translational efforts. Additionally, the specificity of Gas6 for TAM receptors, particularly MerTK, minimizes the potential for off-target effects that can be seen with less selective small molecule inhibitors.

Despite these strengths, several challenges and weaknesses must be considered. First, although preclinical studies support the mechanistic rationale for Gas6 in restoring RPE phagocytosis, there is a significant gap in clinical data; currently, no clinical trials have investigated the use of recombinant Gas6 for dry AMD, and thus its safety and efficacy in human subjects remain unproven (ClinicalTrials.gov, n.d.). Moreover, as a protein-based therapeutic, recombinant Gas6 may face challenges in terms of stability, formulation, and delivery to the retina. The inherent short half-life of many proteins in vivo and potential immunogenicity issues must be addressed, perhaps through advanced drug delivery systems such as nanoparticle encapsulation or sustained-release formulations—strategies that have been explored in other retinal diseases (Wu et al., 2021, pp. 1–2; Wu et al., 2021, pp. 7–10).

Another potential concern is the complexity of TAM receptor signaling in diverse tissue contexts; while selective activation of MerTK on RPE cells is desirable, Gas6 can also engage Axl and Tyro3 receptors, which may have different and even undesired biological effects if activated in non-target tissues (Burstyn-Cohen, 2017, pp. 7–8; Davra et al., 2016, pp. 12–14). Therefore, achieving adequate local concentrations in the retina without eliciting systemic effects or off-target activation will be critical. In addition, the dosing regimen, route of administration (likely intravitreal injection), and long-term safety profile must be rigorously evaluated in preclinical models before progressing to human trials (Inana et al., 2018, pp. 11–12; Huelse et al., 2020, pp. 4–6).

Overall, the compelling mechanistic basis—namely, that recombinant Gas6 engages MerTK to promote actin-driven engulfment and phagosome formation—supports its potential to restore RPE function in dry AMD by enhancing the clearance of photoreceptor outer segments (Miao et al., 2024, pp. 20–21; Axelrod, 2018, pp. 111–114). The fact that Gas6 is an endogenous molecule with well-understood biology further reinforces its appeal as a therapeutic candidate. However, the translational path will require careful formulation work, extensive preclinical validation including pharmacokinetic and toxicology studies, and ultimately, clinical trials to determine efficacy in patients with dry AMD. In conclusion, while recombinant human Gas6 offers a strong mechanistic rationale and a robust biochemical profile as a promoter of MerTK-mediated phagocytosis in RPE cells, its clinical potential for dry AMD will depend on overcoming formulation and delivery challenges and establishing a favorable safety and efficacy profile through rigorous translational research (Albert et al., 2015, pp. 10–11; Unknown Reference; Parinot et al., 2024, pp. 1–2; Davra et al., 2016, pp. 12–14; Sozzi, 2023, pp. 21–25).

In summary, the comprehensive literature review supports that recombinant human Gas6 possesses significant potential as a novel biologic therapeutic candidate for dry AMD. Its natural origin, well-established structure–function relationship, and ability to specifically activate MerTK-mediated signaling in RPE cells position it as a promising agent to restore defective phagocytosis in the retina. The strengths of this candidate include mechanistic clarity, reliance on endogenous signaling pathways, and the availability of established production platforms. The weaknesses, however, lie in the current lack of clinical data and potential challenges in drug delivery and off-target effects. These factors underscore the need for further preclinical studies addressing pharmacokinetics, formulation optimization, and comprehensive safety evaluation before advancing to clinical trials for dry AMD treatment (Miao et al., 2024, pp. 26–28; Inana et al., 2018, p. 15; Law et al., 2015, pp. 7–8; Savage et al., 2015, pp. 60–65; Sawada et al., 2022, p. A939; Wu et al., 2021, pp. 1–2).

References
Albert, R., Kristóf, E., Zahuczky, G., Szatmári-Tóth, M., Veréb, Z., Oláh, B., Moe, M. C., Facskó, A., Fésüs, L., & Petrovski, G. (2015). Triamcinolone regulated apopto-phagocytic gene expression patterns in the clearance of dying retinal pigment epithelial cells: A key role of Mertk in the enhanced phagocytosis. Biochimica et Biophysica Acta (BBA) – General Subjects, 1850(1), 435–446. https://doi.org/10.1016/j.bbagen.2014.10.026

Axelrod, H. D. (2018). The role of Axl in prostate cancer dormancy. [Journal unknown].

Bellan, M., Pirisi, M., & Sainaghi, P. S. (2016). The Gas6/TAM system and multiple sclerosis. International Journal of Molecular Sciences, 17(11), 1807. https://doi.org/10.3390/ijms17111807

Burstyn-Cohen, T. (2017). TAM receptor signaling in development. The International Journal of Developmental Biology, 61, 215–224. https://doi.org/10.1387/ijdb.160285tb

ClinicalTrials.gov. (n.d.). Gas6 AND (macular degeneration OR retinal degeneration). Retrieved from https://clinicaltrials.gov/

Davra, V., Kimani, S., Calianese, D., & Birge, R. (2016). Ligand activation of TAM family receptors: Implications for tumor biology and therapeutic response. Cancers, 8(12), 107. https://doi.org/10.3390/cancers8120107

Evans, A. L. (2016). Evaluation of Mertk evolution and efferocytosis signalling. [Journal unknown].

Huelse, J. M., Fridlyand, D. M., Earp, S., DeRyckere, D., & Graham, D. K. (2020). Mertk in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system. Pharmacology & Therapeutics, 213, 107577. https://doi.org/10.1016/j.pharmthera.2020.107577

Inana, G., Murat, C., An, W., Yao, X., Harris, I. R., & Cao, J. (2018). RPE phagocytic function declines in age-related macular degeneration and is rescued by human umbilical tissue derived cells. Journal of Translational Medicine. https://doi.org/10.1186/s12967-018-1434-6

Law, A.-L., Parinot, C., Chatagnon, J., Gravez, B., Sahel, J.-A., Bhattacharya, S. S., & Nandrot, E. F. (2015). Cleavage of Mer tyrosine kinase (Mertk) from the cell surface contributes to the regulation of retinal phagocytosis. Journal of Biological Chemistry, 290, 4941–4952. https://doi.org/10.1074/jbc.m114.628297

Law, L. A., Graham, D. K., Di Paola, J., & Branchford, B. R. (2018). Gas6/TAM pathway signaling in hemostasis and thrombosis. Frontiers in Medicine, 5, 137. https://doi.org/10.3389/fmed.2018.00137

Miao, Y. R., Rankin, E. B., & Giaccia, A. J. (2024). Therapeutic targeting of the functionally elusive TAM receptor family. Nature Reviews Drug Discovery, 23, 201–217. https://doi.org/10.1038/s41573-023-00846-8

Müller, C., & Finnemann, S. C. (2020). RPE phagocytosis. In Retinal Pigment Epithelium in Health and Disease (pp. 47–63). https://doi.org/10.1007/978-3-030-28384-1_3

Parinot, C. (2015). Étude des mécanismes extracellulaires régulant la fonction du récepteur Mertk au cours de la phagocytose rétinienne. [Journal unknown].

Parinot, C., Chatagnon, J., Rieu, Q., Roux, S., Néel, D., Hamieh, F., & Nandrot, E. F. (2024). Gas6 and protein S ligands cooperate to regulate Mertk rhythmic activity required for circadian retinal phagocytosis. International Journal of Molecular Sciences, 25(12), 6630. https://doi.org/10.3390/ijms25126630

Savage, J. C., Jay, T., Goduni, E., Quigley, C., Mariani, M. M., Malm, T., Ransohoff, R. M., Lamb, B. T., & Landreth, G. E. (2015). Nuclear receptors license phagocytosis by TREM2+ myeloid cells in mouse models of Alzheimer’s disease. The Journal of Neuroscience, 35, 6532–6543. https://doi.org/10.1523/jneurosci.4586-14.2015

Sawada, A., Toyoura, M., Takaiwa, A., Inoue, T., & Nakamura, K. (2022). 901 inhibition of Gas6/Mertk signaling by novel Mertk antibody, 20A77, exerts significant anti-tumor efficacy with little retinal degeneration in mice. Regular and Young Investigator Award Abstracts, A939. https://doi.org/10.1136/jitc-2022-sitc2022.0901

Sozzi, L. (2023). Gas6/TAM system: Potential prognostic biomarkers for multiple sclerosis. [Journal unknown].

Tasnim, T. (2020). Identification of the signalosome and signaling pathway of the efferocytic receptor Mertk. [Journal unknown].

Wu, S., Mao, Y., Liu, Q., Yan, X., Zhang, J., & Wang, N. (2021). Sustained release of Gas6 via MPEG-PLGA nanoparticles enhances the therapeutic effects of Mertk gene therapy in RCS rats. Frontiers in Medicine. https://doi.org/10.3389/fmed.2021.794299

Yefimova, M. G., Ravel, C., Rolland, A. D., Bourmeyster, N., & Jégou, B. (2021). Mertk-mediated LC3-associated phagocytosis (LAP) of apoptotic substrates in blood-separated tissues: Retina, testis, ovarian follicles. Cells, 10(6), 1443. https://doi.org/10.3390/cells10061443
